Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S - Scandinavian Starch for Severe Sepsis/Septic Shock trial): Study protocol, design and rationale for a double-blinded, randomised clinical trial
2011

Comparing Hydroxyethyl Starch and Balanced Crystalloid Solution in Severe Sepsis

Sample size: 800 publication Evidence: moderate

Author Information

Author(s): Perner Anders, Haase Nicolai, Wetterslev Jørn, Åneman Anders, Tenhunen Jyrki, Guttormsen Anne Berit, Klemenzson Gudmundur, Pott Frank, Bødker Karen Doris, Bådstøløkken Per Martin, Bendtsen Asger, Søe-Jensen Peter, Tousi Hamid, Bestle Morten, Pawlowicz Malgorzata, Winding Robert, Bülow Hans-Henrik, Kancir Claude, Steensen Morten, Nielsen Jonas, Fogh Bjarne, Madsen Kristian R, Larsen Nils H, Carlsson Marcela, Wiis Jørgen, Petersen John Asger, Iversen Susanne, Schøidt Ole, Leivdal Siv, Berezowicz Pawel, Pettilä Ville, Ruokonen Esko, Klepstad Pål, Karlsson Sari, Kaukonen Maija, Rutanen Juha, Karason Sigurbergur, Kjældgaard Anne Lene, Holst Lars Broksø, Wernerman Jan

Primary Institution: Copenhagen University Hospital, Rigshospitalet, Denmark

Hypothesis

Does hydroxyethyl starch 130/0.4 improve survival and reduce kidney failure compared to balanced crystalloid solutions in patients with severe sepsis?

Conclusion

The study aims to determine the safety and efficacy of hydroxyethyl starch 130/0.4 in patients with severe sepsis.

Supporting Evidence

  • The study will randomize 800 patients to assess the effects of HES 130/0.4.
  • The primary outcome is a composite of 90-day mortality or end-stage kidney failure.
  • The trial aims to provide important safety and efficacy data on HES 130/0.4.

Takeaway

This study is trying to find out if a specific fluid treatment helps people with a serious infection and kidney problems live longer and feel better.

Methodology

Multicentre, randomised, double-blinded trial comparing 6% HES 130/0.4 in Ringer's acetate to Ringer's acetate alone.

Potential Biases

Potential biases in patient selection and treatment allocation due to the nature of the trial.

Limitations

The study may not account for all variables affecting patient outcomes, and results may not be generalizable beyond the Scandinavian context.

Participant Demographics

Adult patients with severe sepsis from 30 Scandinavian ICUs.

Digital Object Identifier (DOI)

10.1186/1745-6215-12-24

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication